Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: Rp-1664, an Oral Plk4 Inhibitor, and Rp-3467, an Oral Pol Inhibitor -November 15, 2023 at 07:00 am EST

Repare Therapeutics Inc. disclosed polo-like kinase 4 as the target of its RP-1664 development program and reported comprehensive preclinical data for both RP-1664 and the Company?s Pol? inhibitor,...

Related Keywords

,Repare Therapeutics Inc ,Repare Therapeutics ,Markets ,